August 21, 2017 2:22 PM ET

Biotechnology

Company Overview of Spark Therapeutics, Inc.

Executive Profile

Stephen W. Webster

Chief Financial Officer, Spark Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 6 Board Members in 6 different organizations across 10 different industries.

See Board Relationships
56$2,111,625
As of Fiscal Year 2016

Background

Mr. Stephen W. Webster has been the Chief Financial Officer at Spark Therapeutics Inc. since July 2014. Mr. Webster served as Managing Director of Gleacher & Company Securities, Inc. from January 2007 to June 2008. Mr. Webster served as the Chief Financial Officer and Senior Vice President of Optimer Pharmaceuticals, Inc. since June 5, 2012 until 2013 and served as its Principal Accounting Officer and Senior Vice President of Finance. Mr. Webster served as Managing Director ...

Corporate Headquarters

3737 Market Street
Philadelphia, Pennsylvania 19104

United States

Phone: 215-220-9300
Fax: --

Board Members Memberships

Director
Director
2014-Present
Director
2017-Present
Director

Education

BA
Dartmouth College
MBA
University of Pennsylvania - The Wharton School

Other Affiliations

Annual Compensation

Salary$401,346
Total Annual Compensation$401,346

Stocks Options

Restricted Stock Awards$1,456,637
All Other Compensation$38,642
Exercised Options$20,000
Exercised Options Value$938,804
Exercisable Options$90,883
Exercisable Options Value$3,002,203
Unexercisable Options$170,132
Unexercisable Options Value$4,300,494
Total Value of Options$8,241,500
Total Number of Options$281,015

Total Compensation

Total Annual Cash Compensation$654,988
Total Short Term Compensation$401,346
Other Long Term Compensation$1,495,279
Total Calculated Compensation$2,111,625
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Alexander D. Macrae M.B., Ch.B, Ph.D., MRCPCEO, President & Director
Sangamo Therapeutics, Inc.
$697.0K
Matthew Craig Kapusta CEO, Interim CFO & Executive Director
uniQure N.V.
$522.3K
Compensation as of Fiscal Year 2016.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Spark Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.